Influence of quinidine, cimetidine, and ketoconazole on the enantioselective pharmacokinetics and metabolism of metoprolol in rats

Chirality

Volumn 21, Issue 10, 2009, Pages 886-893

  Boralli, Vanessa Bergamin ^a   Coelho, Eduardo Barbosa ^a   Lanchote, Vera Lucia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cytochrome P450 inhibitors; Enantiomers; Metabolites; Metoprolol; Pharmacokinetics; Rats

Indexed keywords

ALPHA HYDROXYMETOPROLOL; CIMETIDINE; CYTOCHROME P450 2D; CYTOCHROME P450 3A; KETOCONAZOLE; METOPROLOL; QUINIDINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; DRUG STRUCTURE; ENANTIOSELECTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIMETIDINE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; FASTING; HYDROGEN-ION CONCENTRATION; KETOCONAZOLE; MALE; METABOLIC CLEARANCE RATE; METOPROLOL; MOLECULAR STRUCTURE; QUINIDINE; RATS; RATS, WISTAR; SPECTROMETRY, FLUORESCENCE; STEREOISOMERISM;

EID: 70350548552     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20682     Document Type: Article

References (21)

1. Dayer P, Leemann T, Marmy A, Rosenthaler J. Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol. Eur J Clin Pharmacol 1985;28:149-153. (Pubitemid 15143775)
2. Wallf T, Webb JG, Bagwell EE, Walle UK, Daniel HB, Gaffney TE. Stereoselective delivery and actions of beta-receptor antagonists. Biochem Pharmacol 1988;37:115-124.
3. Mostafavi AS, Foster RT. Pharmacokinetics of metoprolol enantiomers following single and multiple administration of racemate in rat. Int J Pharm 2000;202:97-102.
4. 1-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm 1974;2:347-364.
5. 3H) in man, the dog and the rat. Acta Pharmacol Toxicol 1975;36:116-124.
6. Murthy SS, Shetty HU, Nelson WL, Jackson PR, Lennard MS. Enantioselective and diastereoselective aspects of the oxidative metabolism of metoprolol. Biochem Pharmacol 1990;40:1637-1644.
7. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 1988;247:242-247.
8. Boralli VB, Coelho EB, Cerqueira PM, Lanchote VL. Stereoselective analysis of metoprolol and its metabolites in rat plasma with application to oxidative metabolism. J Chromatogr B 2005;823:195-202.
9. Madani S, Paine MF, Lewis L, Thummel KE, Shen DD. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res 1999;16:1199-1205. (Pubitemid 29393607)
10. Coulbourne PD, Baker GB, Coutts RT. A rapid e sensitive electron-capture gas chromatographic procedure for analysis of metoprolol in rat brain and heart. J Pharmacol Toxicol Methods 1997;38:27-31.
11. Law MYL, Slawson MH, Moody DE. Selective involvement of cytochrome P450 2D subfamily in in vivo 4-hydroxylation of amphetamine in rat. Drug Metab Dispos 2000;28:348-352.
12. Yuan R, Sumi M, Benet LZ. Investigation of aortic CYP3A bioactivation of nitroglycerin in vivo. J Pharmacol Exp Ther 1997;281:1499-1505. (Pubitemid 27258412)
13. Zhang Y, Hsieh Y, Izumi T. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J Pharmacol Exp Ther 1998;287:246-252. (Pubitemid 29140208)
14. Kageyama M, Namiki H, Fukushima H, Ito Y, Shibata N, Takada K. In vivo effects of cyclosporine A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biol Pharm Bull 2005;28:316-322.
15. Levine M, Law EYW, Bandiera SM. In vivo cimetidine inhibits hepatic CYP2C6 and CYP2C11 but not CYP1A1 in adult male rats. J Pharmacol Exp Ther 1998;284:493-499.
16. Vermeulen AM, Belpaire FM, Smet FD, Vercruysse I, Bogaert MG. Aging and the pharmacokinetics and metabolism of metoprolol enantiomers in the rat. J Gerontol Biol Sci 1993;48:108-114. (Pubitemid 23143651)
17. Cerqueira PM, Boralli VB, Coelho EB, Lopes NP, Guimarães LFL, Bonato PS, Lanchote VL. Enantioselective determination of metoprolol acidic metabolite in plasma and urine using liquid chromatography chiral columns: applications to pharmacokinetics. J Chromatogr B 2003;783:433-441.
18. Tucker GT, Houston NB, Huang SW. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther 2001;70:103-114. (Pubitemid 32777761)
19. Bonnabry P, Sievering J, Leemann T, Dayer P. Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies. Clin Pharmacokinet 2001;40:631-640. (Pubitemid 32954987)
20. Orishiki M, Matsuo Y, Nishioka M, Ichikawa Y. In vivo administration of H2 blockers, cimetidine and ranitidine reduced the contents of cytochrome P450IID (CYP2D) subfamily and their activities in rat liver microsomes. Int J Biochem 1994;26:751-758.
21. Testa R, Ghia M, Mattioli F, Borzone S, Caglieris S, Mereto E, Giannini E, Risso D. Effects off reduced glutathione and n-acetylcysteine on lidocaine metabolism in cimetidine treated rats. Fundam Clin Pharmacol 1998;12:220-224. (Pubitemid 28154613)